Newamsterdam Pharma Stock Revenue
| NAMS Stock | 20.84 0.21 1.00% |
NewAmsterdam Pharma fundamentals help investors to digest information that contributes to NewAmsterdam Pharma's financial success or failures. It also enables traders to predict the movement of NewAmsterdam Stock. The fundamental analysis module provides a way to measure NewAmsterdam Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NewAmsterdam Pharma stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 12.8 M | 12.1 M |
NewAmsterdam | Revenue |
NewAmsterdam Pharma Company Revenue Analysis
NewAmsterdam Pharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current NewAmsterdam Pharma Revenue | 12.76 M |
Most of NewAmsterdam Pharma's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NewAmsterdam Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of NewAmsterdam
Projected quarterly revenue analysis of NewAmsterdam Pharma provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of NewAmsterdam Pharma match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in NewAmsterdam Pharma's stock price.
NewAmsterdam Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for NewAmsterdam Pharma is extremely important. It helps to project a fair market value of NewAmsterdam Stock properly, considering its historical fundamentals such as Revenue. Since NewAmsterdam Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NewAmsterdam Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NewAmsterdam Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
NewAmsterdam Revenue Historical Pattern
Today, most investors in NewAmsterdam Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NewAmsterdam Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of NewAmsterdam Pharma revenue as a starting point in their analysis.
NewAmsterdam Pharma Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
NewAmsterdam Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, NewAmsterdam Pharma reported 12.76 M of revenue. This is 99.83% lower than that of the Biotechnology sector and 98.28% lower than that of the Health Care industry. The revenue for all United States stocks is 99.86% higher than that of the company.
NewAmsterdam Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NewAmsterdam Pharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NewAmsterdam Pharma could also be used in its relative valuation, which is a method of valuing NewAmsterdam Pharma by comparing valuation metrics of similar companies.NewAmsterdam Pharma is currently under evaluation in revenue category among its peers.
NewAmsterdam Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NewAmsterdam Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NewAmsterdam Pharma's managers, analysts, and investors.Environmental | Governance | Social |
NewAmsterdam Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in NewAmsterdam Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of NewAmsterdam Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing NewAmsterdam Pharma's value.| Shares | Polar Capital Holdings Plc | 2024-06-30 | 1 M | Deerfield Management Co | 2024-09-30 | 901.8 K | Gmt Capital Corp | 2024-06-30 | 891.8 K | Avidity Partners Management Lp | 2024-09-30 | 889.7 K | Artal Group S A | 2024-06-30 | 800 K | Pictet Asset Manangement Sa | 2024-06-30 | 683.7 K | Citadel Advisors Llc | 2024-09-30 | 522.5 K | Woodline Partners Lp | 2024-06-30 | 483.4 K | Affinity Asset Advisors, Llc | 2024-09-30 | 472.4 K | Fcpm Iii Services Bv | 2024-09-30 | 11.8 M | Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 10.5 M |
NewAmsterdam Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 1.52 B | ||||
| Shares Outstanding | 92.39 M | ||||
| Shares Owned By Insiders | 0.25 % | ||||
| Shares Owned By Institutions | 84.04 % | ||||
| Number Of Shares Shorted | 718.04 K | ||||
| Price To Book | 5.13 X | ||||
| Price To Sales | 57.89 X | ||||
| Revenue | 12.76 M | ||||
| EBITDA | (165.69 M) | ||||
| Net Income | (160.27 M) | ||||
| Total Debt | 60 K | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (141.22 M) | ||||
| Short Ratio | 2.92 X | ||||
| Earnings Per Share | (2.21) X | ||||
| Target Price | 37.0 | ||||
| Number Of Employees | 62 | ||||
| Beta | -0.001 | ||||
| Market Capitalization | 2.29 B | ||||
| Total Asset | 347.1 M | ||||
| Retained Earnings | (316.97 M) | ||||
| Working Capital | 296.89 M | ||||
| Net Asset | 347.1 M |
About NewAmsterdam Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NewAmsterdam Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewAmsterdam Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewAmsterdam Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.